Nanomedicine for drug targeting: Strategies beyond the enhanced permeability and retention effect

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2539-2555

  Nehoff, Hayley ^a   Parayath, Neha N ^a   Domanovitch, Laura ^a   Taurin, Sebastien ^a   Greish, Khaled ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Cancer treatment; Inflammation; Nanomedicine; Permeability and retention effect; Tissue targeting

Indexed keywords

AMINOSALICYLIC ACID; ANTIBODY; BETAMETHASONE; BEVACIZUMAB; BRADYKININ; CAMPTOTHECIN; DEXAMETHASONE; FOLATE RECEPTOR; GELATINASE A; HISTAMINE; HYDROGEN PEROXIDE; IMATINIB; LEUKOTRIENE DERIVATIVE; MAGNETIC NANOPARTICLE; MONOCLONAL ANTIBODY DC101; NITRIC OXIDE; PEROXYNITRITE; PHOSPHOLIPASE A2; SEROTONIN; TRIPEPTIDE; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; NANOCAPSULE;

BLOOD PRESSURE REGULATION; CANCER CELL; CANCER TISSUE; COLITIS; COLLAGEN-INDUCED ARTHRITIS; COLON CARCINOMA; COLORECTAL CARCINOMA; CONVECTION ENHANCED DELIVERY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME RELEASE; ENZYME SPECIFICITY; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; GASTROINTESTINAL TRACT; HUMAN; LIVER; LUNG NON SMALL CELL CANCER; MAGNETIC FIELD; NANOMEDICINE; NONHUMAN; PERMEABILITY BARRIER; PH; PROTEIN TARGETING; RECTUM CARCINOMA; REVIEW; SPLEEN; THYROID CARCINOMA; TISSUE LEVEL; TISSUE PENETRATION; TISSUE PRESSURE; ULTRASOUND; UVEORETINITIS; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DESIGN; DRUG FORMULATION; INFLAMMATION; METABOLISM; NEOPLASMS; PROCEDURES; ULTRASTRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; DRUG DESIGN; HUMANS; INFLAMMATION; NANOCAPSULES; NEOPLASMS;

EID: 84901436582     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47129     Document Type: Review

References (130)

1. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1): 6387-6392.
2. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-1380.
3. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 1984;44(5):2115-2121.
4. Konno T, Maeda H, Iwai K, et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer. 1984;54(11):2367-2374.
5. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324-4327.
6. Jeon BH, Jang C, Han J, et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 2008;68(4): 1100-1109.
7. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J Control Release. 2012;164(3):265-275.
8. 2. Ann Oncol. 2000;11(8):1029-1033.
9. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of PEGylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-449.
10. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A. 1999;96(6):3137-3142.
11. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature. 2004; 427(6976):695.
12. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806-813.
13. Bingaman S, Huxley VH, Rumbaut RE. Fluorescent dyes modify properties of proteins used in microvascular research. Microcirculation. 2003;10(2):221-231.
14. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731-3736.
15. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565-5570.
16. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-147.
17. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
18. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296(5574): 1883-1886.
19. Uutela M, Wirzenius M, Paavonen K, et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood. 2004;104(10):3198-3204.
20. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929-2934.
21. Vlahovic G, Rabbani ZN, Herndon JE, 2nd, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer. 2006;95(8):1013-1019.
22. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62(19):5476-5484.
23. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release. 2001;74(1-3):7-25.
24. Reichman HR, Farrell CL, Del Maestro RF. Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model. J Neurosurg. 1986;65(2):233-237.
25. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14(2): 97-105.
26. Konishi Y, Muragaki Y, Iseki H, Mitsuhashi N, Okada Y. Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases. Neurol Med Chir (Tokyo). 2012;52(8):577-586.
27. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30(12): 2302-2318.
28. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164(1):2-14.
29. Vinchon-Petit S, Jarnet D, Paillard A, Benoit JP, Garcion E, Menei P. In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. J Neurooncol. 2010;97(2):195-205.
30. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006;66(5):2801-2806.
31. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 2006;8(3):205-214.
32. Inoue T, Yamashita Y, Nishihara M, et al. Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro Oncol. 2009;11(2):151-157.
33. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64(7):2572-2579.
34. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100(3):472-479.
35. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg. 1999;90(2):315-320.
36. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2:14.
37. Horn T, Henriksen JH, Christoffersen P. The sinusoidal lining cells in "normal" human liver. A scanning electron microscopic investigation. Liver. 1986;6(2):98-110.
38. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-1095.
39. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141(3):320-327.
40. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-496.
41. Chakeres DW, de Vocht F. Static magnetic field effects on human subjects related to magnetic resonance imaging systems. Prog Biophys Mol Biol. 2005;87(2-3):255-265.
42. Gao ZG, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release. 2005;102(1):203-222.
43. Rapoport NY, Christensen DA, Fain HD, Barrows L, Gao Z. Ultrasound-triggered drug targeting of tumors in vitro and in vivo. Ultrasonics. 2004;42(1-9):943-950.
44. Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release. 2009;137(1):63-68.
45. Kodama T, Tomita Y, Koshiyama K, Blomley MJ. Transfection effect of microbubbles on cells in superposed ultrasound waves and behavior of cavitation bubble. Ultrasound Med Biol. 2006;32(6):905-914.
46. Huang SL. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1167-1176.
47. Choi JJ, Wang S, Brown TR, Small SA, Duff KE, Konofagou EE. Noninvasive and transient blood-brain barrier opening in the hippocampus of Alzheimer's double transgenic mice using focused ultrasound. Ultrason Imaging. 2008;30(3):189-200.
48. Raymond SB, Treat LH, Dewey JD, McDannold NJ, Hynynen K, Bacskai BJ. Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One. 2008;3(5):e2175.
49. Ting CY, Fan CH, Liu HL, et al. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials. 2012;33(2):704-712.
50. Xie F, Boska MD, Lof J, Uberti MG, Tsutsui JM, Porter TR. Effects of transcranial ultrasound and intravenous microbubbles on blood-brain barrier permeability in a large animal model. Ultrasound Med Biol. 2008;34(12):2028-2034.
51. Konerding MA, Steinberg F, Streffer C. The vasculature of xenotransplanted human melanomas and sarcomas on nude mice. I. Vascular corrosion casting studies. Acta Anat (Basel). 1989;136(1):21-26.
52. Konerding MA, Steinberg F, Streffer C. The vasculature of xenotransplanted human melanomas and sarcomas on nude mice. II. Scanning and transmission electron microscopic studies. Acta Anat (Basel). 1989;136(1):27-33.
53. Andrade SP, Beraldo WT. Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors. Int J Exp Pathol. 1998;79(6):425-432.
54. Kohzuki M, Tanda S, Hori K, et al. Endothelin receptors and angiotensin II receptors in tumor tissue. J Cardiovasc Pharmacol. 1998;31 Suppl 1: S531-S533.
55. Tozer GM, Shaffi KM, Prise VE, Bell KM. Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution. Int J Cancer. 1996;65(5):658-663.
56. Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer. 2002;98(1):29-35.
57. Kennovin GD, Flitney FW, Hirst DG. "Upstream" modification of vasoconstrictor responses in rat epigastric artery supplying an implanted tumour. Adv Exp Med Biol. 1994;345:411-416.
58. Moochhala S, Chhatwal VJ, Chan ST, Ngoi SS, Chia YW, Rauff A. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis. 1996;17(5):1171-1174.
59. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer. 1998;82(10):1897-1903.
60. Dworkin MJ, Carnochan P, Allen-Mersh TG. Effect of continuous regional vasoactive agent infusion on liver metastasis blood flow. Br J Cancer. 1997;76(9):1205-1210.
61. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst. 1981;67(3):663-669.
62. Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer. 1993;67(5):975-980.
63. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 2002;39(2):162-173.
64. Huang R, Ke W, Han L, Li J, Liu S, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials. 2011;32(9):2399-2406.
65. Sun C, Veiseh O, Gunn J, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small. 2008;4(3):372-379.
66. Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006;24(22):3644-3650.
67. Hockaday DC, Shen S, Fiveash J, et al. Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005;46(4):580-586.
68. Ying Z, Tojo H, Komatsubara T, et al. Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma. Biochim Biophys Acta. 1994;1226(2):201-205.
69. Jiang J, Neubauer BL, Graff JR, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol. 2002;160(2):667-671.
70. Lagorce-Pages C, Paraf F, Wendum D, Martin A, Flejou JF. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus. Virchows Arch. 2004;444(5):426-435.
71. Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol. 1996;23(7):1162-1166.
72. Andersen S, Sjursen W, Laegreid A, Volden G, Johansen B. Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue. Inflammation. 1994;18(1):1-12.
73. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jorgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J Med Chem. 2004;47(7): 1694-1703.
74. Jørgensen K, Vermehren C, Mouritsen OG. Enhancement of phospholipase A2 catalyzed degradation of polymer grafted PEG-liposomes: effects of lipopolymer-concentration and chain-length. Pharm Res. 1999;16(9):1491-1493.
75. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66(18):8927-8930.
76. Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J Natl Cancer Inst. 1987;79(6):1205-1211.
77. Griset AP, Walpole J, Liu R, Gaffey A, Colson YL, Grinstaff MW. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J Am Chem Soc. 2009;131(7):2469-2471.
78. Tian WM, Zhang CL, Hou SP, et al. Hyaluronic acid hydrogel as Nogo-66 receptor antibody delivery system for the repairing of injured rat brain: in vitro. J Control Release. 2005;102(1):13-22.
79. Yamashiro DJ, Fluss SR, Maxfield FR. Acidification of endocytic vesicles by an ATP-dependent proton pump. J Cell Biol. 1983;97(3): 929-934.
80. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science. 1980;210(4475): 1253-1255.
81. Yuba E, Tajima N, Yoshizaki Y, Harada A, Hayashi H, Kono K. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy. Biomaterials. 2014;35(9):3091-3101.
82. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2008;25(1):55-71.
83. Cerritelli S, Velluto D, Hubbell JA. PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules. 2007;8(6):1966-1972.
84. Behr JP. The proton sponge: a trick to enter cells the viruses did not exploit. CHIMIA International Journal for Chemistry. 1997; 51(1-2):1-2.
85. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103(2):405-418.
86. Xu ZP, Niebert M, Porazik K, et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. J Control Release. 2008; 130(1):86-94.
87. Hoon Jeong J, Christensen LV, Yockman JW, et al. Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials. 2007;28(10):1912-1917.
88. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005;11(6):990-995.
89. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos. 1995;16(5):351-380.
90. Dressman J, Berardi R, Dermentzoglou L, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7): 756-761.
91. Peppas NA. Devices based on intelligent biopolymers for oral protein delivery. Int J Pharm. 2004;277(1-2):11-17.
92. Colombo P, Sonvico F, Colombo G, Bettini R. Novel platforms for oral drug delivery. Pharm Res. 2009;26(3):601-611.
93. Dai J, Nagai T, Wang X, Zhang T, Meng M, Zhang Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280(1):229-240.
94. Lee CH, Lo LW, Mou CY, Yang CS. Synthesis and characterization of positive-charge functionalized mesoporous silica nanoparticles for oral drug delivery of an anti-inflammatory drug. Adv Funct Mater. 2008; 18(20):3283-3292.
95. Lin YH, Chang CH, Wu YS, Hsu YM, Chiou SF, Chen YJ. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials. 2009;30(19): 3332-3342.
96. Majno G, Palade GE. Studies on inflammation. 1. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol. 1961;11:571-605.
97. Majno G, Shea SM, Leventhal M. Endothelial contraction induced by histamine-type mediators: an electron microscopic study. J Cell Biol. 1969;42(3):647-672.
98. Hulstrom D, Svensjo E. Intravital and electron microscopic study of bradykinin-induced vascular permeability changes using FITC-dextran as a tracer. J Pathol. 1979;129(3):125-133.
99. Lampugnani MG, Dejana E. Interendothelial junctions: structure, signalling and functional roles. Curr Opin Cell Biol. 1997;9(5): 674-682.
100. Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788-793.
101. Kamata R, Yamamoto T, Matsumoto K, Maeda H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect Immun. 1985;48(3): 747-753.
102. Matsumoto K, Yamamoto T, Kamata R, Maeda H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem. 1984;96(3):739-749.
103. Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9(11):923-928.
104. Foxall C, Watson SR, Dowbenko D, et al. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J Cell Biol. 1992;117(4):895-902.
105. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci. 2003;24(12):640-647.
106. Hashida N, Ohguro N, Yamazaki N, et al. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp Eye Res. 2008;86(1):138-149.
107. Minaguchi J, Oohashi T, Inagawa K, Ohtsuka A, Ninomiya Y. Transvascular accumulation of Sialyl Lewis X conjugated liposome in inflamed joints of collagen antibody-induced arthritic (CAIA) mice. Arch Histol Cytol. 2008;71(3):195-203.
108. Song L, Li H, Sunar U, et al. Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int J Nanomedicine. 2007;2(4):767-774.
109. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10(18):2941-2952.
110. Hong G, Yuan R, Liang B, Shen J, Yang X, Shuai X. Folate-functionalized polymeric micelle as hepatic carcinoma-targeted, MRI-ultrasensitive delivery system of antitumor drugs. Biomed Microdevices. 2008;10(5):693-700.
111. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41(2):147-162.
112. Zhang B, Li Y, Fang CY, et al. Receptor-mediated cellular uptake of folate-conjugated fluorescent nanodiamonds: a combined ensemble and single-particle study. Small. 2009;5(23):2716-2721.
113. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54(5):675-693.
114. Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5(3):309-319.
115. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13(3):256-262.
116. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56(8):1177-1192.
117. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther. 2006;5(4):818-824.
118. Turk MJ, Waters DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 2004;213(2):165-172.
119. Osborn MJ, Freeman M, Huennekens FM. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med. 1958;97(2):429-431.
120. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65(12):5317-5324.
121. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750-4755.
122. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010;16(10):2760-2768.
123. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65(24): 11631-11638.
124. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732-6740.
125. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70(15):6303-6312.
126. Yang W, Barth RF, Adams DM, et al. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res. 2002;62(22):6552-6558.
127. Pertuit D, Moulari B, Betz T, et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release. 2007;123(3):211-218.
128. Sakai T, Kohno H, Ishihara T, et al. Treatment of experimental autoimmune uveoretinitis with poly (lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res. 2006;82(4):657-663.
129. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010; 138(3):843-853. e842.
130. Koo OMY, Rubinstein I, Önyüksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res. 2011;28(4):776-787.